Introduction
============

Noonan syndrome (NS) is an autosomal dominant genetic condition that affects one in 1,000--2,500 individuals. Typical signs of NS include characteristic facial features, short stature, congenital heart defect, skeletal and thoracic anomalies, developmental delay, and bleeding problems; these are seen in 30%--72% of patients with the condition.[@b1-jbm-9-185] Until recently, the molecular etiology of NS was unknown; this, coupled with the highly variable phenotype observed in these patients, made diagnosis difficult. It is now recognized, however, that \~50% of patients with NS demonstrate pathological variants of the *PTPN11* gene. This results in the development of NS, or another disorder involving *PTPN11* (such as LEOPARD syndrome), where cardiac defects also frequently manifest as pulmonary valve stenosis and hypertrophic cardiomyopathy.[@b2-jbm-9-185] A number of genes are known to play a role in NS; molecular testing of the four best-recognized genes in NS is now generally available and has identified mutations in *PTPN11* in \~50%, *KRAS* in \<5%, *SOS1* in \~15%, and *RAF1* in 3%--17% of patients with the disorder.[@b3-jbm-9-185]

NS can be associated with an increased risk of bleeding and bruising, and a variety of bleeding abnormalities, with factor XI deficiency and platelet abnormalities being described most frequently.[@b4-jbm-9-185]--[@b6-jbm-9-185] However, it is not clear whether there is any direct correlation between bleeding risk and results of coagulation tests so there is currently increased focus on evaluating bleeding risk in patients with NS. As a consequence of their condition, many patients undergo multiple surgeries, often starting in early childhood, so it is important to establish bleeding risk prior to any intervention. For example, pulmonary valve stenosis, which is often reported in patients with NS, is typically unsuitable for interventional balloon dilation due to bleeding risk, and usually requires surgery for correction. Also, the presence of a partial atrioventricular canal with outflow obstruction can result in a demanding surgical procedure to correct the malformation.[@b7-jbm-9-185] The aim of this systematic review was to identify the frequency and types of bleeding disorders, and to evaluate any links with associated laboratory findings, in patients with NS, with a view to providing physicians with guidelines on how to evaluate bleeding complications in patients with NS.

Methods and results
===================

Publications from 1965 to 2014 were reviewed. They included trials, case reports/series, and reviews identified via MEDLINE^®^, EMBASE^®^, and Scopus^®^. Key search terms included: Noonan; bleed\*3; hemorrhag\*3; thrombocytop\*enia; h\*emostatic; h\*emostasis; bleed\* diathesis; platelet\* disorder\*.

Studies of patients with NS were included in the analysis only if the bleeding phenotype was described. Studies were excluded if NS was not present or not confirmed in all cases; the publication was a secondary analysis (review of other case reports with no new information); there was no patient-level bleeding phenotype information reported for any patients. All available patient data were abstracted, and included demographics, bleeding symptoms, laboratory abnormalities, bleeding score, and specific disorders reported. The numbers of patients in each study are shown in [Table S1](#SD1-jbm-9-185){ref-type="supplementary-material"}.

Of 45 studies identified,[@b1-jbm-9-185],[@b4-jbm-9-185]--[@b6-jbm-9-185],[@b8-jbm-9-185]--[@b48-jbm-9-185] 31[@b4-jbm-9-185]--[@b6-jbm-9-185],[@b8-jbm-9-185]--[@b35-jbm-9-185] had relevant data from 428 patients with NS ([Figure 1](#f1-jbm-9-185){ref-type="fig"}). Of the 31 studies included, 13 were single case studies, five included \<10 patients, and 13 included \>10 patients. The largest cumulative study, including 151 patients,[@b18-jbm-9-185] had previously been reported with 72[@b5-jbm-9-185] and 31[@b33-jbm-9-185] patients; however, different sets of information are presented in each publication. Nearly half (49%) of the patients were male; 43% (183 patients) had reported bleeding, 26% (112 patients) had not reported bleeding, and for 31% (133 patients) there was no data on bleeding. Most patients (384; 90%) had some reported laboratory test abnormalities (platelet function and/or coagulation abnormalities). Of the patients with reported bleeding, abnormal laboratory tests included: prolonged prothrombin time (PT) (29 patients; 7%); activated partial thromboplastin time (aPTT) (71 patients; 17%); PT/aPTT (23 patients; 5%); and platelet-related disorders (42 patients; 10%). There were also reports of normal PT (104 patients; 24%) and aPTT (157 patients; 37%).

In one of the studies of 39 patients (and 28 controls), nearly 40% of patients with NS had a bleeding diathesis but \>90% had platelet function and/or coagulation abnormalities.[@b9-jbm-9-185] Another study of 13 patients suggested that bleeding signs do not appear to be due to coagulation disorders.[@b22-jbm-9-185]

Of the 428 patients evaluated, only 46% (195 patients) had a specific diagnosis of factor deficiency, von Willebrand disease, or platelet-related disorder. Of these patients, 154 (78%) had single-factor deficiencies or von Willebrand disease, and 42 (22%) had multiple factor deficiencies ([Table 1](#t1-jbm-9-185){ref-type="table"}). Of the factor deficiencies, factor XI (FXI) deficiency was most common (81 patients), followed by factor XII (FXII) (34 patients), and factor VIII (FVIII) (28 patients) ([Table 2](#t2-jbm-9-185){ref-type="table"}). Platelet-related disorders were reported in 46 patients, with thrombocytopenia and platelet aggregation abnormality being most commonly reported. In the 42 patients reporting multiple factor deficiencies, FXI+FXII combined (11 patients), and FVIII+ FXI combined (seven patients) were the most common ([Table 2](#t2-jbm-9-185){ref-type="table"}).

Discussion
==========

Physicians are diagnosing NS more readily; however, this literature review identifies a clear gap in the evaluation and diagnosis of bleeding diathesis and specific bleeding disorders in these patients. Indeed, several studies have highlighted that there is no correlation between coagulation study results and bleeding risk. In one study of 39 patients (and 28 controls), whilst only 40% of patients with NS had a bleeding diathesis, more than 90% had platelet function and/or coagulation abnormalities.[@b9-jbm-9-185] Another study of 13 patients suggested that bleeding signs do not appear to be due to coagulation disorders.[@b22-jbm-9-185] These findings suggest that screening needs to include tests beyond PT, aPTT and platelet count. Therefore, guidelines for clinical evaluation in NS should highlight the importance of comprehensive testing, as well as the need for specialist involvement by a pediatric hematologist in differential diagnosis, both at diagnosis of NS and pre-operatively, whenever screening test abnormalities are identified.[@b49-jbm-9-185]

Although there is currently no consensus on the optimum strategy for diagnosis of bleeding in patients with NS, a review by Roberts et al in 2013 suggested that at diagnosis of NS a complete blood cell count (CBC) with differential and PT/aPTT should be undertaken. After diagnosis, repeat CBC with differential and PT/aPTT if aged 6--12 months at initial screen, and pre-operatively, CBC with differential and PT/aPTT, then in consultation with hematologist FIX, FXI and FXII concentrations, von Willebrand factor, and platelet aggregation. Furthermore, if symptomatic, PT/aPTT if bleeding is abnormal or persistent, then refer to a hematologist.[@b50-jbm-9-185]

Due to the inconsistent reporting of platelet test results and platelet disorders in the studies included in this analysis, it does not appear that appropriate tests are being undertaken in clinical practice. Platelet aggregation, for example, needs to be conducted on a fresh specimen and is more likely to be offered at regional centers. It is therefore important to distinguish between abnormalities in platelet function suspected by screening tests (eg, platelet function analysis-100) and confirmed platelet function disorders based upon aggregometry patterns and confirmed with flow cytometry, electron microscopy, or genetic testing.

The surprisingly high incidence of multiple coagulation disorders suggests that work up in patients with NS needs to be more comprehensive. While FXI deficiency was most common individually and in combination, there were several multiple defects (both factor deficiencies and platelet function disorders) reported in the same patient.

Given that several germline mutations including *PTPN11* and *SOS1* are reported in patients with NS, there may be a possible correlation with bleeding phenotype. However, of the studies included in our analysis, only a few evaluated genetic mutations in relation to the reported bleeding disorder and results were not consistent. An evaluation of patients with NS reported *PTPN11* gene mutations in 21 of 27 patients, and hematological disorders in nine of 27, with authors suggesting a near significant correlation.[@b12-jbm-9-185] Another study of 19 patients with NS showed that coagulation abnormalities were reported in patients with *PTPN11*, *SOS1* and *SOS1*/*RAF1* mutations and without a gene mutation, but they were not correlated with a specific gene mutation.[@b14-jbm-9-185] In addition, a study of 13 patients with NS (six with *PTPN11* mutations) found that 12/13 had normal hematological assessment and only one had a platelet function disorder (storage pool disease).[@b22-jbm-9-185] One of the studies of 15 patients (14 with *PTPN11* mutation and one with *SOS1* mutation), showed that nine had a bleeding diathesis and complained of easy bruising, despite having normal platelet count, basic coagulation parameters, fibrinogen and antithrombin, and without a relevant reduction of coagulation factor activities. Furthermore, three of them had potentially acquired von Willebrand disease, which the authors suggested may explain the bleeding in those with pulmonary stenosis.[@b47-jbm-9-185] Further analysis of a large cohort of individuals with NS has suggested that *PTPN11* gene mutations are more likely to be found in those with pulmonary stenosis, whereas hypertrophic cardiomyopathy is less prevalent among those with *PTPN11* mutations.[@b2-jbm-9-185] Thus, bleeding disorders in NS do not appear to correlate with a particular genotype.

There are limitations to this analysis, which included mostly spontaneous case reports/series, because the reporting of symptoms, laboratory evaluations, and diagnosis may have been incomplete. Furthermore, while attempts were made to remove duplicate reporting of the same case in both an individual case report and prior compiled series/review, there may have been cases that were not explicitly referenced. When limited coagulation evaluation does not confirm to one or more specific diagnoses, it underscores the importance of referral to a pediatric hematologist so that the patient's parents can give a detailed bleeding history. This should then be followed through with a differential diagnosis, using appropriate laboratory assays. In future case reports/series, there is an important need to ensure that symptoms, laboratory results, and ultimate diagnoses are tracked.

Conclusion
==========

Patients with NS can experience multiple bleeding disorders, including platelet-related disorders. Comprehensive clinical evaluations should be carried out both at diagnosis, after diagnosis if patients are symptomatic, and prior to any surgical procedures, even if tests are normal, the risk for bleeding events should be carefully considered. Furthermore, as there is no current consensus on management of bleeding complications in patients with NS, it is important that physicians closely monitor these patients.

Supplementary materials
=======================

###### 

Case reports/series on bleeding disorders in patients with NS

  Reference                                                                         Number of patients
  --------------------------------------------------------------------------------- ----------------------------------------------
  Argyrou A, et al. *Arch Hell Med*, 2010[@b51-jbm-9-185]                           1
  Artoni A, et al. *Pediatrics*, 2014[@b52-jbm-9-185]                               39
  Bertola DR, et al. *Rev Hosp Clin Fac Med Sao Paulo*, 2003[@b53-jbm-9-185]        30
  González Casado I, et al. *Horm Res Paediatr*. 2011[@b54-jbm-9-185]               27
  de Haan M, et al. *Am J Med Genet*. 1988[@b55-jbm-9-185]                          12
  Flick JT, et al. *Am J Clin Pathol*. 1991[@b56-jbm-9-185]                         1
  Gamba G, et al. *Horm Res Paediatr*. 2011[@b57-jbm-9-185]                         19
  Kitchens CS, et al. *J Pediatr*. 1983[@b58-jbm-9-185]                             4
  Koc A, et al. *Turk J Haematol*. 2001[@b59-jbm-9-185]                             1
  Massarano AA, et al. *Acta Paediatr*. 1996[@b60-jbm-9-185]                        18
  Nunes P, et al. *BMJ Case Rep*. 2012[@b61-jbm-9-185]                              1
  Patrick K, et al. *Br J Haematol*. 2010[@b62-jbm-9-185]                           1
  Sharland M, et al. *Arch Dis Child*. 1992[@b63-jbm-9-185]                         151[a](#tfn6-jbm-9-185){ref-type="table-fn"}
  Sharland M, et al. *Lancet*. 1992[@b64-jbm-9-185]                                 72[a](#tfn6-jbm-9-185){ref-type="table-fn"}
  Staudt JM, et al. *Scand J Plast Reconstr Surg Hand Surg*. 2005[@b65-jbm-9-185]   1
  Stoffman JM, et al. *Blood*. 2004[@b66-jbm-9-185]                                 28
  Tanaka Y, et al. *Am J Med Genet*. 1999[@b67-jbm-9-185]                           2
  Troiano M, et al. *Horm Res Paediatr*. 2011[@b68-jbm-9-185]                       13
  Vortia E, et al. *Am J Gastroenterol*. 2011[@b69-jbm-9-185]                       2
  Waespe N, et al. *Hämostaseologie*. 2013[@b70-jbm-9-185]                          15
  Witt DR, et al. *Am J Med Genet*. 1988[@b71-jbm-9-185]                            19
  Caralis DG, et al. *Johns Hopkins Med J*. 1974[@b72-jbm-9-185]                    1
  Evans DG, et al. *Clin Genet*. 1991[@b73-jbm-9-185]                               1
  Grange CS, et al. *Can J Anaesth*. 1998[@b74-jbm-9-185]                           1
  Humbert JA, et al. *Lancet*. 1970[@b75-jbm-9-185]                                 1
  Komp DM, et al. *Pediatr Res*. 1975[@b76-jbm-9-185]                               2
  Phillips WG, et al. *Br J Dermatol*. 1993[@b77-jbm-9-185]                         1
  Sgouros SN, et al. *J Gastroenterol Hepatol*. 2004[@b78-jbm-9-185]                1
  Sharland M, et al. *J Med Genet*. 1990[@b79-jbm-9-185]                            31[a](#tfn6-jbm-9-185){ref-type="table-fn"}
  Singer ST, et al. *J Pediatr Hematol Oncol*. 1997[@b80-jbm-9-185]                 3
  Sugar AW, et al. *J Oral Maxillofac Surg*. 1994[@b81-jbm-9-185]                   1

**Note:**

Substudies (31 and 72 of 151 patients from Sharland et al. *Arch Dis Child*. 1992).[@b13-jbm-9-185]

**Abbreviation:** NS, Noonan syndrome.
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###### 

Factor deficiencies and other bleeding disorders reported in patients with NS

  Type of deficiency                                          Single factor deficiency   Multiple factor deficiency   Total
  ----------------------------------------------------------- -------------------------- ---------------------------- ---------
  FI                                                          2                          1                            3
  FII                                                         0                          1                            1
  FV                                                          0                          5                            5
  FVII                                                        6                          6                            12
  FVIII                                                       18                         12                           30
  FIX                                                         4                          7                            11
  FX                                                          0                          5                            5
  FXI                                                         57                         30                           87
  FXII                                                        19                         16                           35
  FXIII                                                       1                          0                            1
  vWD                                                         4                          6                            10
  Platelet-related[a](#tfn1-jbm-9-185){ref-type="table-fn"}   42                         5                            47
  **Total[b](#tfn2-jbm-9-185){ref-type="table-fn"}**          **153**                    **42**                       **195**

**Notes:**

Thrombocytopenia: 20 (two were transient after birth); ITP + cyclooxygenase deficiency: 1; Bernard--Soulier syndrome: 1; platelet aggregation abnormality: 19; platelet storage pool deficiency: 1.

Total is the number of patients with factor deficiencies, and for multiple factor deficiencies patients could have more than one deficiency type.

**Abbreviations:** ITP, idiopathic thrombocytopenia; FI, factor I; FII, factor II; FV, factor V; FVII, factor VII; FVIII, factor VIII; FIX, factor IX; FX, factor X; FXI, factor XI, FXII, factor XII; FXIII, factor XIII; NS, Noonan syndrome; vWD, von Willebrand disease.

###### 

Multiple factor deficiencies and platelet-related disorders reported in patients with NS

  Multiple factor deficiency                Number of patients
  ----------------------------------------- --------------------
  FI + FXI + FXII                           1
  FII + FXI                                 1
  FV + FVII + FX                            1
  FV + FVIII                                3
  FV + FIX + FX                             1
  FVII + FIX + FXI + vWD                    2
  FVII + FX                                 2
  FVII + FXII + platelet-related disorder   1
  FVIII + FXI + FXII                        1
  FVIII + vWD                               1
  FVIII + FXI                               7
  FIX + FX                                  1
  FIX + FXII + platelet-related disorder    1
  FIX + FXI                                 2
  FXI + FXII                                11
  FXI + vWD                                 2
  FXI + platelet-related disorder           3
  FXII + vWD                                1
  **Total**                                 **42**

**Notes:**

Platelet-related disorders included: thrombocytopenia; idiopathic thrombocytopenic purpura + cyclooxygenase deficiency; Bernard--Soulier syndrome, platelet aggregation abnormality; platelet storage pool deficiency.

**Abbreviations:** FI, factor I; FII, factor II; FV, factor V; FVII, factor VII; FVIII, factor VIII; FIX, factor IX; FX, factor X; FXI, factor XI, FXII, factor XII; FXIII, factor XIII; NS, Noonan syndrome; vWD, von Willebrand disease.
